Minireviews
Copyright ©The Author(s) 2023.
World J Hepatol. Nov 27, 2023; 15(11): 1188-1195
Published online Nov 27, 2023. doi: 10.4254/wjh.v15.i11.1188
Figure 1
Figure 1 Benefits and risks of ruxolitinib use in terms of opportunistic infections in myeloproliferative neoplasms. MPNs: Myeloproliferative neoplasms; RUX: Ruxolitinib; HBVr: Hepatitis B virus reactivation; NK cells: Natural killer cells.